Samsung, Merck Look To Take On Sanofi’s Lantus With Latest Deal
This article was originally published in PharmAsia News
Executive Summary
In the latest win for Samsung Bioepis, the Korean company will help develop and manufacture a late-stage insulin glargine candidate with Merck.